Irbesartan Rowa

Irbesartan, the active ingredient in Irbesartan Rowa, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It lowers blood pressure by blocking AT1 receptors and is used to treat hypertension in adult patients.\n\nGNH India supplies Irbesartan Rowa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control elevated blood pressure and protect the kidneys.\n\n- Hypertension: reduces systolic and diastolic pressure, helping prevent cardiovascular complications.\n- Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes with proteinuria.\n- Heart failure (adjunct therapy): improves symptoms and may reduce hospitalisation when combined with standard heart‑failure regimens.

Common Side Effects:\n- Dizziness: sensation of light‑headedness, especially after standing.\n- Headache: mild to moderate pain in the head region.\n- Fatigue: feeling unusually tired or weak.\n- Upper respiratory infection: mild cold‑like symptoms.\n- Hyperkalemia: elevated blood potassium levels, often asymptomatic.\n\nSerious or Rare Side Effects:\n- Angioedema: rapid swelling of face, lips, tongue or throat requiring emergency care.\n- Acute renal failure: sudden loss of kidney function, indicated by reduced urine output.\n- Severe hyperkalemia: potassium levels >6.0 mmol/L, risking cardiac arrhythmia.\n- Hepatic injury: elevated liver enzymes or jaundice.\n- Hypotension: marked drop in blood pressure causing faintness.

Irbesartan should be used with careful monitoring and patient education.\n\n- Blood pressure monitoring: check regularly to ensure therapeutic control.\n- Renal function assessment: evaluate serum creatinine and eGFR before and during therapy.\n- Serum potassium surveillance: monitor especially if combined with potassium‑sparing agents.\n- Hepatic impairment caution: dose may need adjustment in patients with liver disease.\n- Pregnancy avoidance: discontinue if pregnancy is confirmed due to fetal risk.\n- Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, requiring clinical vigilance.\n\nMajor Interactions (Avoid):\n- Aliskiren (in diabetes): combined use can increase renal impairment and hyperkalemia.\n- Potassium‑sparing diuretics (e.g., spironolactone): risk of dangerous hyperkalemia.\n- ACE inhibitors: concurrent use raises angioedema risk.\n- NSAIDs: may blunt antihypertensive effect and affect renal function.\n- Lithium: increased lithium levels leading to toxicity.\n\nModerate Interactions (Monitor Closely):\n- Thiazide diuretics: may enhance hypotensive effect, requiring dose titration.\n- Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood‑pressure lowering.\n- CYP3A4 inhibitors (e.g., fluconazole): modest increase in irbesartan plasma concentrations.\n- CYP3A4 inducers (e.g., rifampin): may reduce irbesartan effectiveness.\n- Antidiabetic agents: improved glycaemic control may necessitate dose adjustment.